BRIEF-Trovagene announces expansion of key claims for its NPM1 patent portfolio
* Trovagene announces expansion of key claims for its npm1 patent portfolio for acute myeloid leukemia
April 28 Guangzhou Wondfo Biotech Co Ltd :
* Says it plans to invest 2.55 million yuan to set up a bio-tech JV in Shandong with partner, and to own 51 percent stake in JV
Source text in Chinese: goo.gl/Gd2MgD
Further company coverage: (Beijing Headline News)
* Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model Source text for Eikon: Further company coverage:
June 19 Seattle Genetics Inc said it would halt a late-stage study of its drug to treat a type of leukemia in older patients following a "higher rate" of deaths in patients on the drug compared with those on a placebo.